FINDINGS:
Comparison: 2023-06-01.
Pulmonary parenchyma: No focal consolidation or suspicious pulmonary nodules. No pneumothorax.
Mediastinum: Enlarged paratracheal lymph node, short axis 31 mm. Cardiomediastinal contours within normal limits.
Pleura/Pleural spaces: No pleural effusion or pleural thickening.
Great vessels/Aorta: No thoracic aortic aneurysm or dissection.
Liver: 67 mm lobulated hepatic mass in segment 7 of the liver (hyperenhancing). No focal hepatic lesions. Normal attenuation.
Spleen: Normal in size and attenuation. No focal splenic lesion.
Pancreas: Normal pancreatic contour and enhancement. No focal mass. no pancreatic mass.
Adrenal glands: Adrenal glands are normal without nodules.
Kidneys: No hydronephrosis. No enhancing renal mass. kidneys are normal.
GI tract/Bowel: No obstructive process. No focal bowel wall mass identified. no bowel obstruction.
Mesentery/Omentum: No ascites. No omental caking.
Mesenteric vessels (SMA/SMV): SMA/SMV are patent without thrombosis.
Urinary bladder: Unremarkable. under-distension wall thickening.
Reproductive organs: No adnexal mass. Uterus/prostate within expected size for age.
Lymph nodes: No pathologically enlarged lymph nodes by size criteria.
Bones/Osseous structures: 31 mm lesion in the bone, suspicious for metastasis. No aggressive osseous lesion. No acute fracture. no destructive osseous lesion.

IMPRESSION:
- Liver primary malignancy at segment 7 of the liver measuring approximately 67 mm.
- Findings concerning for nodal involvement.
- Findings compatible with distant metastases involving: bone.
- RECIST 1.1 Summary:
- Target lesions (n=3; ≤2 per organ rule applied).
  • T1: Primary — 61→67 mm (longest diameter).
  • T2: Metastasis — 28→31 mm (longest diameter).
  • T3: Lymph node — 29→31 mm (short axis).
- SLD baseline: 118 mm.
- SLD current: 129 mm (+9.3% change).
- New lesions: absent (unequivocal).
- - RECIST 1.1 overall response category: PD.
